Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
LVTX 
LAVA Therapeutics NV (LVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: LVTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.52
1 Year Target Price $1.52
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.93% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.77M USD | Price to earnings Ratio - | 1Y Target Price 1.52 |
Price to earnings Ratio - | 1Y Target Price 1.52 | ||
Volume (30-day avg) 4 | Beta 0.5 | 52 Weeks Range 0.85 - 1.82 | Updated Date 12/11/2025 |
52 Weeks Range 0.85 - 1.82 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-11-26 | When - | Estimate -0.245 | Actual -0.27 |
Profitability
Profit Margin - | Operating Margin (TTM) -431.92% |
Management Effectiveness
Return on Assets (TTM) -19.92% | Return on Equity (TTM) -101.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3892787 | Price to Sales(TTM) 9.17 |
Enterprise Value -3892787 | Price to Sales(TTM) 9.17 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA 0.81 | Shares Outstanding 26305295 | Shares Floating 17565624 |
Shares Outstanding 26305295 | Shares Floating 17565624 | ||
Percent Insiders 16.38 | Percent Institutions 27.54 |
Upturn AI SWOT
LAVA Therapeutics NV
Company Overview
History and Background
LAVA Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing a new class of bispecific antibody-based immunotherapy for solid tumors. Founded in 2014, it emerged from the academic research of Professor Hans van der Vliet and Dr. Jacques J.M. van de Winkel. The company's core technology platform, GOGENTA, aims to overcome the limitations of existing immunotherapies. LAVA Therapeutics has advanced its lead candidates into clinical trials, indicating a significant evolution from its founding research to therapeutic development.
Core Business Areas
- Immunotherapy Development: LAVA Therapeutics NV is dedicated to the discovery and development of novel bispecific antibody-based immunotherapies. Their primary focus is on activating the immune system to target and eliminate solid tumor cells. The company utilizes its proprietary GOGENTA platform to engineer these bispecific antibodies.
Leadership and Structure
LAVA Therapeutics NV is led by a management team with expertise in biotechnology and drug development. Key leadership positions typically include a Chief Executive Officer, Chief Medical Officer, Chief Scientific Officer, and Chief Financial Officer. The company operates under a typical corporate structure for a publicly traded biopharmaceutical company, with a Board of Directors overseeing strategic decisions and management responsible for day-to-day operations.
Top Products and Market Share
Key Offerings
- Product Name 1: LAVA-051: Description: LAVA-051 is a bispecific antibody designed to target CD1d on NKT cells and tumor-associated antigens. It aims to activate NKT cells to kill tumor cells. Market Share Data: Not Applicable (Early Stage Clinical Development). Competitors: Companies developing CAR-NK cell therapies, bispecific antibodies targeting other immune cells for solid tumors, and other novel immunotherapies for hematological malignancies and solid tumors.
- Product Name 2: LAVA-082: Description: LAVA-082 is another bispecific antibody candidate under development by LAVA Therapeutics, also based on their GOGENTA platform. Specific target antigens and indications are subject to ongoing development and clinical trial progression. Market Share Data: Not Applicable (Early Stage Clinical Development). Competitors: Similar to LAVA-051, competitors would include companies with novel immunotherapy approaches for solid tumors.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology sector, is characterized by rapid innovation, significant investment in research and development, and a highly competitive landscape. The demand for effective cancer treatments, especially immunotherapies, continues to grow. Key trends include the development of personalized medicine, combination therapies, and novel drug delivery systems. The market is driven by unmet medical needs and advancements in scientific understanding of cancer biology.
Positioning
LAVA Therapeutics NV is positioned as an innovator in the immunotherapy space, focusing on a differentiated bispecific antibody approach to harness the power of NKT cells for cancer treatment. Their proprietary GOGENTA platform offers a unique mechanism of action. The company's competitive advantage lies in its novel technology, which aims to overcome limitations of current therapies, and its focus on solid tumors, a significant area of unmet need.
Total Addressable Market (TAM)
The TAM for oncology therapeutics, particularly immunotherapies for solid tumors, is in the hundreds of billions of dollars globally and is projected to continue growing significantly. LAVA Therapeutics NV is positioned to address a substantial portion of this market by developing therapies for various solid tumor indications. Their success will depend on the efficacy and safety of their drug candidates in clinical trials and their ability to secure market access.
Upturn SWOT Analysis
Strengths
- Proprietary GOGENTA platform for bispecific antibody development.
- Focus on activating NKT cells, a unique immunotherapy approach.
- Potential to address significant unmet medical needs in solid tumors.
- Experienced management and scientific team.
- Clinical-stage assets with ongoing trials.
Weaknesses
- Early-stage company with limited revenue generation.
- Reliance on successful clinical trial outcomes.
- High burn rate associated with R&D and clinical development.
- Limited brand recognition and market presence compared to established players.
Opportunities
- Growing demand for effective cancer immunotherapies.
- Potential for strategic partnerships and collaborations.
- Expansion into new indications and tumor types.
- Advancements in understanding tumor microenvironment and immune cell interactions.
- Potential for orphan drug designation and accelerated approval pathways.
Threats
- Clinical trial failures or unexpected safety issues.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Regulatory hurdles and delays in drug approval processes.
- Pricing pressures and reimbursement challenges.
- Emergence of superior or more cost-effective alternative therapies.
Competitors and Market Share
Key Competitors
- CAR-NK Cell Therapy Developers (e.g., Artiva Biotherapeutics Inc. - no US symbol available for direct comparison)
- Bispecific Antibody Developers (e.g., Amgen Inc. - AMGN, Bristol Myers Squibb Company - BMY, Regeneron Pharmaceuticals, Inc. - REGN)
- Other Novel Immunotherapy Developers (e.g., Moderna, Inc. - MRNA, BioNTech SE - BNTX)
Competitive Landscape
LAVA Therapeutics NV competes in a highly dynamic and innovation-driven field. Its advantages lie in its novel GOGENTA platform and NKT cell activation approach. However, it faces disadvantages in terms of scale, resources, and established market presence compared to large pharmaceutical companies. Competitors may have broader pipelines, larger clinical trial capacities, and established manufacturing and commercialization infrastructure.
Growth Trajectory and Initiatives
Historical Growth: LAVA Therapeutics NV's historical growth has been characterized by the progression of its scientific platform and pipeline candidates from preclinical research into clinical trials. This growth is measured by milestones such as IND filings, initiation of clinical studies, and achievement of clinical endpoints.
Future Projections: Future projections for LAVA Therapeutics NV are highly speculative and contingent on the success of its ongoing clinical trials for LAVA-051 and LAVA-082. Analyst estimates, if available, would focus on potential market penetration, peak sales projections upon approval, and the overall growth of the immunotherapy market for solid tumors.
Recent Initiatives: Recent initiatives likely include the advancement of their lead drug candidates into clinical trials, potential new target identification, and expansion of their research collaborations. The company may also be focused on securing additional funding to support its ongoing development programs and potential manufacturing scale-up.
Summary
LAVA Therapeutics NV is an early-stage biopharmaceutical company with a promising novel immunotherapy platform. Its GOGENTA technology, focused on NKT cell activation for solid tumors, represents a significant opportunity. However, the company faces considerable risks associated with clinical trial success, intense competition, and the high costs of drug development. Strong execution of its clinical strategy and successful funding rounds will be critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Press Releases and Investor Relations.
- Financial News Outlets (e.g., Bloomberg, Reuters).
- Biotechnology Industry Analysis Reports.
- ClinicalTrials.gov for ongoing trial information.
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial or investment advice. Investment in biotechnology stocks, especially early-stage companies, is highly speculative and carries significant risks. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LAVA Therapeutics NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-25 | CEO, President & Executive Director Mr. Stephen Allen Hurly M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.lavatherapeutics.com |
Full time employees 10 | Website https://www.lavatherapeutics.com | ||
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.